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There is a shortage of medical isotopes in the world today.
Two of the most important isotope producing reactors, the
NationalResearchUniversal(NRU)reactorinCanadaandthe
High Flux Reactor (HFR) in the Netherlands, are currently
under repair. The main consequence is that the supply of
99Mo, the workhorse isotope of nuclear medicine, is far
below the medical demand. This demand comes from >30
million patients worldwide that are diagnosed each year
using
99mTc, the daughter isotope of
99Mo. Supply shortages
will remain the case until these two reactors are returned to
service. However, both these reactors are close to 50 years
old, as are the three other main isotope producing reactors
(BR2, Belgium, OSIRIS, France and SAFARI, South Africa,
Fig. 1). Since it is expected that the clinical demand for
99mTc will remain strong for decades to come [1, 2], the
remaining life time of these reactors is too short. The future
of a significant part of nuclear medicine is therefore
dependent on new reactors being built, or on new technol-
ogies being developed.
In several countries, the present shortage has given rise
to studies on possible ways to resolve the problem. In
Canada, it was originally planned to replace the NRU by
two so-called MAPLE reactors, but that project was
discontinued for technical reasons [3]. Subsequently, at
the initiative of the Canadian Government, an independent
expert panel reviewed a large number of different proposals
for
99Mo production, in order to advise on the way forward
[4]. In the USA a committee investigated options to move
away from the current use of highly enriched uranium
(HEU) as target material for
99Mo production [5]. In the
Netherlands, a new multipurpose reactor Pallas [6] has
been proposed. This prompted the Dutch government to
commission an independent review of all possibilities to
produce
99Mo in the future [7].
Such an important issue as the production of
99Mo has
political, economic and scientific aspects. In this editorial
we focus on a scientific comparison of all the options, using
the results of the independent committees as a basis. First
we discuss the current technology of irradiating HEU plates
in reactors. Then we describe the possible alternatives for
99Mo production in four broad categories: molybdenum
targets in reactors, target plates in accelerators,
99Mo
extraction from liquid reactors and the replacement of the
HEU targets by low enriched uranium (LEU). Finally we
present conclusions, which are supported by the indepen-
dent reviews mentioned above.
Current technology: uranium targets in a reactor
Almost all
99Mo production today comes from research
reactors. Targets containing uranium are placed inside the
reactor, where neutrons cause fission of
235U atoms inside
the target. Many isotopes are formed by these fission
processes and these include
99Mo, so-called fission product
99Mo. After about 1 week of irradiation, the targets are
taken from the reactor for chemical processing. The targets
are dissolved in either an acid or alkaline solution and the
99Mo is extracted chemically.
An important advantage of this technology is the high
production rate. This production rate is determined by the
combination of three factors: the number of neutrons
available that cause fission (flux), the mass of
235U
available (target) and the probability of fission when a
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reactors all three factors are large; the flux and the target
space in research reactors are high in both cases and the
natural probability of fission is also very high (see Table 1
for a comparison with the alternative processes). Another
feature favouring fission is that a large proportion of the
molybdenum produced is the desired
99Mo. This means that
the material produced has a high level of radioactivity per
gram of molybdenum (high specific activity).
There are also downsides. The chemical processing of
targets creates liquid chemical waste that is highly
radioactive and this must be processed and safely stored.
Also, the procedure uses HEU, which is strategically
sensitive material.
Alternative 1: molybdenum targets in a reactor
A first alternative is to irradiate molybdenum targets in a
reactor. Neutrons can be captured by
98Mo atoms to form
99Mo. The chemical processing after irradiation is relatively
simple, as one only needs to dissolve the molybdenum
target and there is no complicated extraction process.
Indeed this process was used for many years before the
introduction of fission product
99Mo.
The production rate, however, is a problem. The
probability that
98Mo captures a neutron is rather low
compared to
235U fission (see Table 1). With the other
factors that influence the production rate roughly equal, the
production rate from a
98Mo target is 250 times lower than
fission, even for an expensive 100% enriched
98Mo target.
Perhaps more importantly, only a tiny fraction of the
original molybdenum is converted to
99Mo in the process.
The fraction of
99Mo per gram molybdenum is 1,000 times
lower compared to the current technology, leading to much
lower radioactivity per gram of molybdenum. This low
specific activity
99Mo product would not work with today’s
99mTc generators and would cause a problem with some
99mTc imaging kits. The design of the
99mTc generators
used to deliver the product to hospitals could be modified.
This would have significant impact on the generator and
imaging kit technology and it is unclear whether this is
feasible to change.
To separate
99Mo from the rest of the molybdenum, there
is research [8] into the possibility of using the recoil of the
99Mo that is caused by the neutron capture of
98Mo. This
Fig. 1 The contribution of the
five most important reactors to
world
99Mo production
Reaction Cross section
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Reactor Current, alternative 3, 4 n+
235U →
99Mo+xx + 2n (586×6% =) 35
Alternative 1 n+
98Mo →
99Mo 0.14
Accelerator Alternative 2 γ+
238U →
99Mo+xx + 2n 0.16×6%
γ+
100Mo →
99Mo+n 0.16
p+
100Mo →
99Mo+p+n 0.15
p+
100Mo →
99mTc + 2n 0.20
Table 1 Nuclear reaction types
for the various proposals
n neutron, γ photon, p proton,
xx other fission products
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ratio and needs to be scaled up. If this research is fruitful,
the problem of the production rate still remains.
GE Hitachi Nuclear Energy (press release, 25 January
2010) will develop a
99Mo production method by placing
molybdenum targets in commercial nuclear power reactors.
As explained above, this method will have a low
production rate. On the other hand, power reactors have
the advantage of very large target volumes, so production
of large quantities of very low specific activity
99Mo is
theoretically possible.
Alternative 2: accelerators
To avoid the use of reactors, accelerators are often
proposed. When charged particles such as protons or
electrons are accelerated to high enough energies, nuclear
reactions can be induced in a target. The most commonly
proposed reactions are listed in Table 1. In some cases, high
energy photons are proposed instead of charged particles.
The method using photon-induced fission of
238U was
recently proposed on the basis of computer simulations [9],
but this has yet to be demonstrated and would need to be
scaled up for mass production.
Accelerator methods using molybdenum as target mate-
rial suffer from the same problem as molybdenum targets in
reactors: the final product contains mostly inactive molyb-
denum, because only a tiny fraction of the molybdenum
target is converted to
99Mo.
The last reaction shown in Table 1 does not produce
99Mo, but directly produces
99mTc. The 6-h half-life of
99mTc implies that it is only possible to distribute it to a
local regional area from a single production centre. Also,
another form of technetium (
99gTc) is produced simulta-
neously with the
99mTc in three times larger quantities
(A.J. Koning, S. Qaim & M.C. Duijvestijn, to be
published). This additional inactive technetium could have
negative effects upon some
99mTc imaging kits.
An important advantage of accelerators is that they
produce relatively less waste than reactors. Also, most
accelerators require less investment than reactors.
The disadvantage of accelerators is the low production
rate. For all the reactions listed in Table 1, the interaction
probability is more than 250 times lower than the present
fission process. In principle the flux of accelerated particles
can be made higher than in a reactor, but this requires the
development of new, even higher power accelerators.
Perhaps more importantly, the useful irradiation volume
(target size) in an accelerator is much smaller than in a
reactor.
Therefore, the only remedy would be to build many
accelerators. Independent expert panels have estimated that
500 accelerators would be needed, of a type that has yet to
be developed. This would require a significant research
effort and substantial investment with significant risks.
A US Scientific Advisory Committee did recommend,
recently, the building of an accelerator for isotope produc-
tion [10]. This advice, though, was for medical isotopes
other than
99Mo, because there is an important category of
medical isotopes that can be better produced using accel-
erators. The worldwide production level required for these
isotopes is far lower than for
99Mo.
There are also proposals to couple an accelerator to a
sub-critical reactor. The advantage would be that the flux
produced by the accelerator is boosted by the chain reaction
in the reactor. In essence, however, this option is building
both a reactor and an accelerator, instead of just one of
them.
Alternative 3: liquid reactors
Instead of placing uranium targets in a reactor or an
accelerator, one can also dissolve uranium in water. When
one fills a vessel of say 150 l with uranyl nitrate, this can
be made critical as an aqueous homogeneous reactor,
containing a few kilogram of uranium. Once a week, the
solution could be transferred to a hot cell for processing
and the molybdenum chemically extracted. Afterwards,
the remaining solution has to be fed back into the reactor,
otherwise the
99Mo yield per kilogram of uranium would
be very low.
The principle of this technology has been proven, with a
reactor power of the order of 200 kW. Assuming that all of
the
99Mo yield of a liquid reactor could be extracted every
week, then, based on a comparison with present experience,
around 20 liquid reactors would be required to produce the
present world demand.
Advantages of liquid reactors are claimed to be an
efficient use of neutrons, elimination of targets and lower
costs.
The drawback of this technology is that it is not yet
mature. An International Atomic Energy Agency
(IAEA) report [11] lists many items that need further
research, starting with determining whether this reactor
type can be operated reliably for prolonged periods. The
combination of the uranium solution and chemical
processing has to be optimized, especially in view of the
need to recycle the solution. This also means that the
chemical cocktail in the reactor will be different after
every production run. Since this reactor type is new, the
license process for building and operating the reactor will
be in uncharted territory. The suitability of the final
99Mo
product in existing
99mTc generator designs is also not
known.
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Alternative 4: conversion from HEU to LEU
There is the possibility to continue operations with more or
less the current technology, but replacing HEU targets by
LEU ones. LEU has by definition less than 20% of the
fissile isotope
235U. The present targets for
99Mo produc-
tion, though, are so far still made of HEU, for the reasons
outlined below.
When an HEU target is directly replaced by an
equivalent LEU target, the number of
235U atoms is reduced
by a factor of 5, and so is the
99Mo production rate. To
counter this effect, a different alloy of uranium and
aluminium with increased uranium density can be used
and thicker targets made. Such targets are currently used in
Argentina for
99Mo production to serve the local market.
Compared to the current technology, these targets have a
two to three times lower
99Mo yield.
Materials are under development with even higher
uranium densities. An example is the uranium silicide that
is used as reactor fuel in the HFR, but it is not easy to
chemically extract the molybdenum from this material.
There are also alloys of uranium and molybdenum with
very high uranium densities, but these alloys encounter the
same problem as molybdenum targets: the initial molybde-
num in the target also ends up in the final product leading
to low specific activity
99Mo.
Conclusions
In summary, the current production rate of
99Mo is based on
the combination of high flux reactors, with significant
target volume and the high natural probability of the
nuclear fission reaction. All alternative techniques have to
face the challenges of lower reaction rates and smaller
target volumes. These can only be overcome by fundamen-
tal technical breakthroughs in areas such as separation
technology, extremely high accelerator beam fluxes or
special extraction techniques. It is unlikely that such
breakthroughs will be achieved during the remaining life
time of the reactors that currently produce
99Mo. Therefore,
we arrive at the following conclusions:
1. The use of molybdenum targets leads to an activity per
gram of molybdenum that is low. Even if this problem
could be solved, the production quantities will be low.
2. Accelerators have a low production rate, so many of
them would be needed to cover world supply. Direct
production of
99mTc has a lower activity per gram of
technetium giving potential technical problems and has a
logistic limitation because of the
99mTc half-life of 6 h.
3. Liquid reactors hold a promise for the future, but parts
of the necessary technology need further research. The
license process and the operational challenges and
economics of this type of reactor are presently
unknown. A significant number of liquid reactors
would be needed to cover world supply.
4. Conversion of the HEU targets to LEU, using
currently available technology, leads to a reduction
in production capacity by a factor of 2–3. Given the
current crisis in production levels, it is difficult to
see how this conversion can be implemented in the
short term and without building additional reactor
capacity.
Reactors will therefore remain necessary for the fore-
seeable future. The best way to secure the supply of
99Mo
for the more than 30 million patients each year is to build
new research reactors to replace the old ones and to ensure
sufficient total production capacity worldwide.
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